Patients
malignancies, anaplastic lymphoma
MALIGNANCIES, CERVICAL CANCER
The included patients were divided into Part A (c-MET overexpression) and Part B (The key exclusion criteria were 1) any other malignancies within five years (except for cured cervical cancer in situ, skin squamous cell carcinoma or papillary thyroid cancer); 2) prior treatment with other hepatocyte growth factor (HGF)/c-MET small-molecule inhibitors or HGF/c-MET monoclonal antibodies, including cabozantinib, merestinib, glesatinib, emibetuzumab, ficlatuzumab, etc.; 3) confirmed anaplastic lymphoma kinase (